Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles P Sparrow

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Inflammatory Bowel Diseases|September 3, 2010
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel diseaseMelissa L Haines, Yousef Ajlouni, Peter M Irving, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel diseaseThomas W T Lee, John H Iser, Miles P Sparrow, et al.
Journal of Crohn'S & Colitis|May 28, 2026
The introduction of an intestinal ultrasound service is associated with significantly reduced endoscopy usage in an inflammatory bowel disease service-the SCOPELESS studyGrace S Feng, Robert D Little, Zaid Ardalan, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel diseaseDavid J Gibson, Mark G Ward, Clarissa Rentsch, et al.
European Journal of Gastroenterology & Hepatology|February 2, 2024
Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel diseaseTamara Mogilevski, Anke L Nguyen, Mary Ajamian, et al.
Alimentary Pharmacology & Therapeutics|October 10, 2024
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel DiseasesRupert W Leong, Anthony Sakiris, Arteen Arzivian, et al.
Journal of Gastroenterology and Hepatology|September 4, 2020
Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's diseaseRaphael P Luber, Luke Dawson, Stephanie Munari, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 25, 2023
Perceived dietary intolerances, habitual intake and diet quality of patients with an ileoanal pouch: Associations with pouch phenotype (and behaviour)Zaid S Ardalan, Katherine M Livingstone, Louise Polzella, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 23, 2013
A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapyGeoffrey M Forbes, Marian J Sturm, Rupert W Leong, et al.
Journal of Clinical Medicine|October 27, 2022
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous BiologicsRobert D Little, Mark G Ward, Emily Wright, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Inflammatory Bowel Diseases|September 3, 2010
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel diseaseMelissa L Haines, Yousef Ajlouni, Peter M Irving, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel diseaseThomas W T Lee, John H Iser, Miles P Sparrow, et al.
Journal of Crohn'S & Colitis|May 28, 2026
The introduction of an intestinal ultrasound service is associated with significantly reduced endoscopy usage in an inflammatory bowel disease service-the SCOPELESS studyGrace S Feng, Robert D Little, Zaid Ardalan, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel diseaseDavid J Gibson, Mark G Ward, Clarissa Rentsch, et al.
European Journal of Gastroenterology & Hepatology|February 2, 2024
Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel diseaseTamara Mogilevski, Anke L Nguyen, Mary Ajamian, et al.
Alimentary Pharmacology & Therapeutics|October 10, 2024
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel DiseasesRupert W Leong, Anthony Sakiris, Arteen Arzivian, et al.
Journal of Gastroenterology and Hepatology|September 4, 2020
Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's diseaseRaphael P Luber, Luke Dawson, Stephanie Munari, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 25, 2023
Perceived dietary intolerances, habitual intake and diet quality of patients with an ileoanal pouch: Associations with pouch phenotype (and behaviour)Zaid S Ardalan, Katherine M Livingstone, Louise Polzella, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 23, 2013
A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapyGeoffrey M Forbes, Marian J Sturm, Rupert W Leong, et al.
Journal of Clinical Medicine|October 27, 2022
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous BiologicsRobert D Little, Mark G Ward, Emily Wright, et al.
Pageof 10